Optimization of antigen dose for a receptorbinding domain-based subunit vaccine against MERS coronavirus

Jian Tang, Naru Zhang, Xinrong Tao, Guangyu Zhao, Yan Guo, Chien-Te Tseng, Shibo Jiang, Lanying Du, Yusen Zhou

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Middle East respiratory syndrome (MERS) is an emerging infectious disease caused by MERS coronavirus (MERS-CoV). The continuous increase of MERS cases has posed a serious threat to public health worldwide, calling for development of safe and effective MERS vaccines. We have previously shown that a recombinant protein containing residues 377– 588 of MERS-CoV receptor-binding domain (RBD) fused with human Fc (S377-588-Fc) induced highly potent anti-MERSCoV neutralizing antibodies in the presence of MF59 adjuvant. Here we optimized the doses of S377-588-Fc using MF59 as an adjuvant in order to elicit strong immune responses with minimal amount of antigen. Our results showed that S377-588-Fc at 1 mg was able to induce in the immunized mice potent humoral and cellular immune responses. Particularly, S377-588-Fc at 1 mg elicited strong neutralizing antibody responses against both pseudotyped and live MERS-CoV similar to those induced at 5 and 20 mg, respectively. These results suggest that this RBD-based subunit MERS vaccine candidate at the dose as low as one mg is sufficiently potent to induce strong humoral and cellular immune responses, including neutralizing antibodies, against MERS-CoV infection, thus providing guidance for determining the optimal dosage of RBD-based MERS vaccines in the future clinical trials and for applying the dosesparing strategy in other subunit vaccine trials.

Original languageEnglish (US)
Article numberA026
Pages (from-to)1244-1250
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Volume11
Issue number5
DOIs
StatePublished - 2015

Fingerprint

Coronavirus Infections
Subunit Vaccines
Antigens
Neutralizing Antibodies
Vaccines
Humoral Immunity
Cellular Immunity
Emerging Communicable Diseases
Middle East Respiratory Syndrome Coronavirus
Recombinant Proteins
Antibody Formation
Public Health
Clinical Trials

Keywords

  • Antigen doses
  • MERS
  • MERS-CoV
  • Receptor-binding domain
  • Subunit vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Optimization of antigen dose for a receptorbinding domain-based subunit vaccine against MERS coronavirus. / Tang, Jian; Zhang, Naru; Tao, Xinrong; Zhao, Guangyu; Guo, Yan; Tseng, Chien-Te; Jiang, Shibo; Du, Lanying; Zhou, Yusen.

In: Human Vaccines and Immunotherapeutics, Vol. 11, No. 5, A026, 2015, p. 1244-1250.

Research output: Contribution to journalArticle

Tang, Jian ; Zhang, Naru ; Tao, Xinrong ; Zhao, Guangyu ; Guo, Yan ; Tseng, Chien-Te ; Jiang, Shibo ; Du, Lanying ; Zhou, Yusen. / Optimization of antigen dose for a receptorbinding domain-based subunit vaccine against MERS coronavirus. In: Human Vaccines and Immunotherapeutics. 2015 ; Vol. 11, No. 5. pp. 1244-1250.
@article{7a7cfd628cdd4daa948f3dddd0d05557,
title = "Optimization of antigen dose for a receptorbinding domain-based subunit vaccine against MERS coronavirus",
abstract = "Middle East respiratory syndrome (MERS) is an emerging infectious disease caused by MERS coronavirus (MERS-CoV). The continuous increase of MERS cases has posed a serious threat to public health worldwide, calling for development of safe and effective MERS vaccines. We have previously shown that a recombinant protein containing residues 377– 588 of MERS-CoV receptor-binding domain (RBD) fused with human Fc (S377-588-Fc) induced highly potent anti-MERSCoV neutralizing antibodies in the presence of MF59 adjuvant. Here we optimized the doses of S377-588-Fc using MF59 as an adjuvant in order to elicit strong immune responses with minimal amount of antigen. Our results showed that S377-588-Fc at 1 mg was able to induce in the immunized mice potent humoral and cellular immune responses. Particularly, S377-588-Fc at 1 mg elicited strong neutralizing antibody responses against both pseudotyped and live MERS-CoV similar to those induced at 5 and 20 mg, respectively. These results suggest that this RBD-based subunit MERS vaccine candidate at the dose as low as one mg is sufficiently potent to induce strong humoral and cellular immune responses, including neutralizing antibodies, against MERS-CoV infection, thus providing guidance for determining the optimal dosage of RBD-based MERS vaccines in the future clinical trials and for applying the dosesparing strategy in other subunit vaccine trials.",
keywords = "Antigen doses, MERS, MERS-CoV, Receptor-binding domain, Subunit vaccines",
author = "Jian Tang and Naru Zhang and Xinrong Tao and Guangyu Zhao and Yan Guo and Chien-Te Tseng and Shibo Jiang and Lanying Du and Yusen Zhou",
year = "2015",
doi = "10.1080/21645515.2015.1021527",
language = "English (US)",
volume = "11",
pages = "1244--1250",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "5",

}

TY - JOUR

T1 - Optimization of antigen dose for a receptorbinding domain-based subunit vaccine against MERS coronavirus

AU - Tang, Jian

AU - Zhang, Naru

AU - Tao, Xinrong

AU - Zhao, Guangyu

AU - Guo, Yan

AU - Tseng, Chien-Te

AU - Jiang, Shibo

AU - Du, Lanying

AU - Zhou, Yusen

PY - 2015

Y1 - 2015

N2 - Middle East respiratory syndrome (MERS) is an emerging infectious disease caused by MERS coronavirus (MERS-CoV). The continuous increase of MERS cases has posed a serious threat to public health worldwide, calling for development of safe and effective MERS vaccines. We have previously shown that a recombinant protein containing residues 377– 588 of MERS-CoV receptor-binding domain (RBD) fused with human Fc (S377-588-Fc) induced highly potent anti-MERSCoV neutralizing antibodies in the presence of MF59 adjuvant. Here we optimized the doses of S377-588-Fc using MF59 as an adjuvant in order to elicit strong immune responses with minimal amount of antigen. Our results showed that S377-588-Fc at 1 mg was able to induce in the immunized mice potent humoral and cellular immune responses. Particularly, S377-588-Fc at 1 mg elicited strong neutralizing antibody responses against both pseudotyped and live MERS-CoV similar to those induced at 5 and 20 mg, respectively. These results suggest that this RBD-based subunit MERS vaccine candidate at the dose as low as one mg is sufficiently potent to induce strong humoral and cellular immune responses, including neutralizing antibodies, against MERS-CoV infection, thus providing guidance for determining the optimal dosage of RBD-based MERS vaccines in the future clinical trials and for applying the dosesparing strategy in other subunit vaccine trials.

AB - Middle East respiratory syndrome (MERS) is an emerging infectious disease caused by MERS coronavirus (MERS-CoV). The continuous increase of MERS cases has posed a serious threat to public health worldwide, calling for development of safe and effective MERS vaccines. We have previously shown that a recombinant protein containing residues 377– 588 of MERS-CoV receptor-binding domain (RBD) fused with human Fc (S377-588-Fc) induced highly potent anti-MERSCoV neutralizing antibodies in the presence of MF59 adjuvant. Here we optimized the doses of S377-588-Fc using MF59 as an adjuvant in order to elicit strong immune responses with minimal amount of antigen. Our results showed that S377-588-Fc at 1 mg was able to induce in the immunized mice potent humoral and cellular immune responses. Particularly, S377-588-Fc at 1 mg elicited strong neutralizing antibody responses against both pseudotyped and live MERS-CoV similar to those induced at 5 and 20 mg, respectively. These results suggest that this RBD-based subunit MERS vaccine candidate at the dose as low as one mg is sufficiently potent to induce strong humoral and cellular immune responses, including neutralizing antibodies, against MERS-CoV infection, thus providing guidance for determining the optimal dosage of RBD-based MERS vaccines in the future clinical trials and for applying the dosesparing strategy in other subunit vaccine trials.

KW - Antigen doses

KW - MERS

KW - MERS-CoV

KW - Receptor-binding domain

KW - Subunit vaccines

UR - http://www.scopus.com/inward/record.url?scp=84939161916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939161916&partnerID=8YFLogxK

U2 - 10.1080/21645515.2015.1021527

DO - 10.1080/21645515.2015.1021527

M3 - Article

C2 - 25874632

AN - SCOPUS:84939161916

VL - 11

SP - 1244

EP - 1250

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 5

M1 - A026

ER -